Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1Ab21-BCMA CAR-T Cells for First-line Consolidation Therapy of Multiple Myeloma With Renal Dysfunction
NCT07489534Phase 2Recruiting
- Sponsor
- Daihong Liu
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PD-1Ab21-BCMA CAR-T in multiple myeloma (MM), sponsored by Daihong Liu. Started Sep 2025; status: recruiting.
02
Drugs
PD-1Ab21-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07489534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489534.